Ir al menú principal
Ir al contenido principal
Ir al pie de página
Para
Medicare
Para
Proveedores
Para
Agentes
Para
Empleadores
English
Para individuos y familias:
Para individuos y familias
Médica
Dental
Otros seguros complementarios
Explorar cobertura a través de tu empleador
Cómo comprar seguros de salud
Tipos de seguro dental
Período de Inscripción Abierta vs. Período Especial de Inscripción
Ver todos los temas
Comprar planes de Medicare
Guía para miembros
Buscar un médico
Ingresar a myCigna
Inicio
Centro de información
Biblioteca del bienestar
Omalizumab for Asthma
Omalizumab for Asthma
Topic Overview
Omalizumab (Xolair) is a medicine approved by the U.S. Food and Drug Administration (FDA) for use in people age 12 and older who have moderate or severe persistent asthma. This medicine costs a lot more than any of the standard treatments for asthma.
The medicine works by blocking immunoglobulin E (IgE) from attaching to allergens. When IgE attaches to an allergen, it sets off a process that leads to the symptoms of an allergic reaction.
This medicine may help reduce asthma episodes, improve peak expiratory flow (PEF), and reduce the need for other medicines. It may also reduce emergency room visits and hospital stays. But more study is needed.
Omalizumab is given as a shot. The dose depends on your body weight and IgE level.
Your doctor may recommend this medicine if:
- Your asthma is not well controlled after using inhaled corticosteroids and long-acting beta2-agonists or leukotriene pathway modifiers for 3 months. People who use oral or injected corticosteroids or who need high doses of inhaled corticosteroids for daily control can also consider using this medicine.
- You have severe allergic asthma and your symptoms aren't relieved by avoiding allergens or taking other medicines.
Severe allergic reactions, including anaphylaxis, can occur with omalizumab, but this is rare. So people who get this medicine are watched for 2 hours after they get their first 2 doses. They should also carry epinephrine in case they have an allergic reaction after treatment.
References
References
Other Works Consulted
- Chung KF, et al. (2014). International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 43(2): 343–373. DOI: 10.1183/09031936.00202013. Accessed March 11, 2014.
Current as of: July 31, 2024
Author: Ignite Healthwise, LLC Staff
Clinical Review Board
All Ignite Healthwise, LLC education is reviewed by a team that includes physicians, nurses, advanced practitioners, registered dieticians, and other healthcare professionals.
This information does not replace the advice of a doctor. Ignite Healthwise, LLC, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.
To learn more about Ignite Healthwise, LLC, visit webmdignite.com.
© 2024-2025 Ignite Healthwise, LLC.
Enlaces relacionados
Asthma in Children
Asthma in Teens and Adults
<cipublic-spinner variant="large"><span>Loading…</span></cipublic-spinner>